159 related articles for article (PubMed ID: 10234725)
41. [Thrombocytopenia due to heparin therapy. Use of danaparoid (Orgaran), 13 monocentric cases under authorization of temporary prescription (ATU)].
Gindre L; de Maistre E; Perrin A; Lecompte T; Hoffman MA
Therapie; 1997; 52(6):591-7. PubMed ID: 9734113
[TBL] [Abstract][Full Text] [Related]
42. Use of danaparoid during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia.
Olin DA; Urdaneta F; Lobato EB
J Cardiothorac Vasc Anesth; 2000 Dec; 14(6):707-9. PubMed ID: 11139115
[No Abstract] [Full Text] [Related]
43. [Thrombopenia induced by heparin: treatment with Org 10172. Tolerability and efficacy].
Tardy-Poncet B; Reynaud J; Tardy B; Mahul P; Mismetti P; Beraud AM; Rebaud MA; Bayon M; Guyotat D
Presse Med; 1996 May 4-11; 25(16):751-5. PubMed ID: 8692750
[TBL] [Abstract][Full Text] [Related]
44. Anticoagulative management of patients requiring left ventricular assist device implantation and suffering from heparin-induced thrombocytopenia type II.
Christiansen S; Jahn UR; Meyer J; Scheld HH; Van Aken H; Kehrel BE; Hammel D
Ann Thorac Surg; 2000 Mar; 69(3):774-7. PubMed ID: 10750760
[TBL] [Abstract][Full Text] [Related]
45. Heparin-induced thrombocytopenia in the cardiovascular patient: diagnostic and treatment guidelines.
Gurbuz AT; Elliott WG; Zia AA
Eur J Cardiothorac Surg; 2005 Jan; 27(1):138-49. PubMed ID: 15621486
[TBL] [Abstract][Full Text] [Related]
46. New treatment options for heparin-induced thrombocytopenia.
Ortel TL; Chong BH
Semin Hematol; 1998 Oct; 35(4 Suppl 5):26-34; discussion 35-6. PubMed ID: 9855181
[TBL] [Abstract][Full Text] [Related]
47. The use of a low molecular weight heparinoid (Org 10172) for extracorporeal procedures in patients with heparin dependent thrombocytopenia and thrombosis.
Rowlings PA; Mansberg R; Rozenberg MC; Evans S; Murray B
Aust N Z J Med; 1991 Feb; 21(1):52-4. PubMed ID: 1709804
[TBL] [Abstract][Full Text] [Related]
48. Heparin-induced thrombocytopenia in the critical care setting: diagnosis and management.
Napolitano LM; Warkentin TE; Almahameed A; Nasraway SA
Crit Care Med; 2006 Dec; 34(12):2898-911. PubMed ID: 17075368
[TBL] [Abstract][Full Text] [Related]
49. Heparin induced thrombocytopenia: diagnosis and management update.
Ahmed I; Majeed A; Powell R
Postgrad Med J; 2007 Sep; 83(983):575-82. PubMed ID: 17823223
[TBL] [Abstract][Full Text] [Related]
50. [Thrombosis of a cardiopulmonary bypass circuit despite recommended hypocoagulation with danaparoid during the acute phase of type II heparin-induced thrombocytopenia].
Salmi L; Elalamy I; Leroy-Matheron C; Houel R; Thébert D; Duvaldestin P
Ann Fr Anesth Reanim; 2006; 25(11-12):1144-8. PubMed ID: 17174213
[TBL] [Abstract][Full Text] [Related]
51. Anticoagulation in patients with heparin-induced thrombocytopenia type II.
Harenberg J; Huhle G; Piazolo L; Wang LU; Heene DL
Semin Thromb Hemost; 1997; 23(2):189-96. PubMed ID: 9200346
[TBL] [Abstract][Full Text] [Related]
52. Argatroban, a new treatment option for heparin-induced thrombocytopenia.
Cleveland KW
Crit Care Nurse; 2003 Dec; 23(6):61-6. PubMed ID: 14692173
[No Abstract] [Full Text] [Related]
53. Heparin-induced thrombocytopenia (HIT) and thrombosis in a haemodialysis-dependent patient with systemic vasculitis.
Roe SD; Cassidy MJ; Haynes AP; Byrne JL
Nephrol Dial Transplant; 1998 Dec; 13(12):3226-9. PubMed ID: 9870499
[No Abstract] [Full Text] [Related]
54. Alternative anticoagulation management strategies for the patient with heparin-induced thrombocytopenia undergoing cardiac surgery.
Murphy GS; Marymont JH
J Cardiothorac Vasc Anesth; 2007 Feb; 21(1):113-26. PubMed ID: 17289495
[No Abstract] [Full Text] [Related]
55. [Current status of anticoagulants].
Oger E; Mottier D
Presse Med; 2000 May 27-Jun 3; 29(19):1079-82. PubMed ID: 10874921
[TBL] [Abstract][Full Text] [Related]
56. Anticoagulation with recombinant hirudin following bone marrow transplantation in a patient with activated protein C resistance and heparin-induced antibodies showing cross-reactivity to the heparinoid danaparoid.
Sauer M; Gruhn B; Fuchs D; Altermann WW; Greinacher A; Völpel H; Zintl F
Med Pediatr Oncol; 1999 Jun; 32(6):457-8. PubMed ID: 10358710
[No Abstract] [Full Text] [Related]
57. Clinical presentation, temporal relationship, and outcome in thirty-three patients with type 2 heparin-induced thrombocytopenia after cardiotomy.
Wan C; Warner M; De Varennes B; Ergina P; Cecere R; Lachapelle K
Ann Thorac Surg; 2006 Jul; 82(1):21-6. PubMed ID: 16798180
[TBL] [Abstract][Full Text] [Related]
58. Successful use of danaparoid in two pregnant women with heart valve prosthesis and heparin-induced thrombocytopenia Type II (HIT).
Gerhardt A; Scharf RE; Zotz RB
Clin Appl Thromb Hemost; 2009; 15(4):461-4. PubMed ID: 18840630
[TBL] [Abstract][Full Text] [Related]
59. [Anticoagulants in clinical practice].
Boneu B
Rev Prat; 1999 Oct; 49(15):1641-7. PubMed ID: 10581994
[TBL] [Abstract][Full Text] [Related]
60. Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management.
Shantsila E; Lip GYH; Chong BH
Chest; 2009 Jun; 135(6):1651-1664. PubMed ID: 19497901
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
